Navigation Links
Mouse Study Shows How Pot Clouds Memory
Date:3/1/2012

THURSDAY, March 1 (HealthDay News) -- Scientists studying mice say they better understand how marijuana impairs working memory, the ability to momentarily retain and utilize information needed for comprehension and learning.

The study, published in the March 2 print issue of Cell, found that THC, the chief psychoactive ingredient in marijuana, impairs memory by affecting passive support cells known as astroglia, not active neurons as previously thought.

The memory changes are a major downside to the use of medical marijuana, the researchers said.

With these experiments in mice, "we have found that the starting point for this phenomenon -- the effect of marijuana on working memory -- is the astroglial cells," researcher Giovanni Marsicano, of INSERM in France, said in a journal news release. Evidence is mounting that these cells play a more active role than once believed in connecting neurons, not just nourishing them, he noted.

The study authors said these cells, also known as astrocytes, could have additional effects on other forms of memory. They said their findings shed light on how the brain works and could eventually help scientists find a way to deal with working memory problems stemming from other causes.

Research involving animals should be considered preliminary because the results often don't have implications for humans.

More information

The U.S. National Institute on Drug Abuse has more about the health effects of marijuana.

-- Mary Elizabeth Dallas

SOURCE: Cell, news release, March 1, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Mouse Study Suggests Alzheimers Spreads Through Brain Like an Infection
2. Mouse Study Give Clues to Why Exercise Is Healthy
3. Gene expression in mouse neural retina sequenced
4. UGA researchers develop first mouse model to study important aspect of Alzheimer’s
5. Drinking Patterns Affect Heart Health, Mouse Study Finds
6. Mouse Study Could Give New Clues to Fighting Baldness
7. New mouse model for testing cancer drugs
8. Human Stem Cells Used to Fix Damaged Mouse Heart
9. Mouse Study Uncovers the Roots of Gray Hair
10. Mouse Study Reveals How Smoking Helps Keep People Thin
11. Apples Help Keep Muscles Strong, Mouse Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Mouse Study Shows How Pot Clouds Memory
(Date:8/31/2015)... Los Angeles, CA (PRWEB) , ... August 31, 2015 , ... ... to start from and those who are interested in learning more about the procedure ... Dr. Parsa Mohebi. , Internationally recognized hair transplant surgeon Parsa Mohebi will be ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Sundance Film Festival award winning documentary ... , “Alive Inside” shadows a social worker who advocates for the use of music ... about bringing music to residents in health care centers who may have lost a ...
(Date:8/31/2015)... ... August 31, 2015 , ... Garden State Urology is celebrating ... of a merger of five of the busiest urology practices in Morris County. ... cost-effective and higher quality care than they did individually. Their mission statement ...
(Date:8/31/2015)... ... ... Presents, Dr. Michael Betsy! Dr. Betsy has been reviewed and approved as an “NJ ... Don Bosco Prep in 1990 and was Class Salutatorian. He earned Varsity letters in ... year. He was inducted into the National Honor Society as a sophomore, was an ...
(Date:8/31/2015)... Nashville, TN (PRWEB) , ... August 31, 2015 , ... ... and how it may be prevented during Amblyopia Awareness Month. Only a comprehensive eye ... is the most common cause of visual impairment among children, affecting approximately 2 to ...
Breaking Medicine News(10 mins):Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2Health News:Public Invited to Dementia Documentary Screening at North Carolina Retirement Community 2Health News:NJ Top Docs Presents, Garden State Urology! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 3
... The College of Optometrists in Vision,Development (COVD) ... O.D., FCOVD, was installed as its 29th president ... Meeting held on,October 20. Dr. Fortenbacher, 53, who ... for eight years, assumes the new role and ...
... Nov. 2 Addressing more than,100 cardiologists and ... chairman and CEO, set out four critical priorities ... today at,Schering-Plough,s fourth annual Cardiovascular Summit in advance ... In his speech, Hassan emphasized the potential ...
... 2 This week in Washington,experts and activists on ... Yoweri Museveni, acting on concerns raised by a number ... the US,to give a speech on AIDS policy, sponsored ... President Bush., "Ugandans deserve respect and recognition for ...
... But most humans couldn,t maintain such a low-cal diet, ... Cutting back drastically on daily calorie intake can lead ... at Buffalo researchers. , They speculate that this kind ... age, slowing the progression to disability. , A lifelong ...
... 2 Shoot For a Cure, the 15th anniversary,celebration ... Hospital, will be held at 6 p.m. Thursday, Nov. ... This year,s celebration will honor Bloomfield resident Penny B.,Blumenstein, ... System. The evening will include an auction, dinner ...
... Nov. 2 ABR-Affinity,BioReagents, a leading global antibody manufacturer, ... Society for,Neuroscience Meeting in San Diego, California, November 3 ... past week and a half, the influx of meeting,participants ... hard hit,economy of the region. "All of the staff ...
Cached Medicine News:Health News:Dr. Dan L. Fortenbacher, O.D., FCOVD, Becomes 29th President of 'College of Optometrists in Vision Development' (COVD); Unveils 7-Part Development Plan for Ongoing Growth 2Health News:Dr. Dan L. Fortenbacher, O.D., FCOVD, Becomes 29th President of 'College of Optometrists in Vision Development' (COVD); Unveils 7-Part Development Plan for Ongoing Growth 3Health News:Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment 2Health News:President Museveni's Visit Protested by HIV/AIDS Experts 2Health News:Calorie-Starved Rats Live Longer: Study 2Health News:ABR-Affinity BioReagents Announces Its Continued Support for the Society for Neuroscience Annual Meeting in San Diego, November 3 - 7, 2007 2
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited ... and development of innovative therapeutics for the treatment of ... today announced that its BNC101 IND submission has passed ... Bionomics plans to initiate a Phase 1 clinical trial ... with metastatic pancreatic cancer prior to 31 December 2015. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... multiple sclerosis, remained relapse-free after three years of treatment ... active brain lesions - the ... - MS, a devastating disease causing progressive disability, affects 2.5 ... including many young adults - FTY720 regulatory filings planned before ...
... basis of methotrexate,resistance and differences in methotrexate response, ... analysis,of the genetic determinants of resistance to the ... could offer a,pathway to predicting such resistance and ... Children,s Research Hospital study., Besides its use ...
Cached Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
... CSV-1000E contrast sensitivity chart test face is the ... world. This test provides for four (4) rows ... of 8 ft (2.5 meters), these gratings test ... 18 cycles/degree. The CSV-1000E provides a full contrast ...
Medicine Products: